Vitrolife AB reported its fourth-quarter 2024 earnings, showcasing a solid performance with sales reaching SEK 959 million, a 6% increase in local currencies. Despite missing the earnings per share ...
Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback